Skip to content
Operation Infinite Justice – Lifestyle
Author:
Artelo Biosciences
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury
July 1, 2026
Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026
June 30, 2026
Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026
June 29, 2026
Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success
June 10, 2026
Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results
May 14, 2026
Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development
April 28, 2026
Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile
April 20, 2026
Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements
April 7, 2026
Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
March 30, 2026
Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
March 27, 2026
1
2
Next Page
→